2020 World Congress Program At-A-Glance

Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

The conversation discusses attending a presentation by Pelage at the Academy of Dermatology Annual Meeting in Denver, focusing on hair loss treatments. Participants express interest in obtaining information or trial compounds related to hair loss solutions like Minoxidil, finasteride, and RU58841.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.